Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 330 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Mellitus II Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

NCT01293669
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jonesboro, Arkansas • Mountain Home, Arkansas • Buena Park, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 2Phase 3 Interventional

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

NCT00395031
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

NCT00403481
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 14, 2026, 4:15 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diabetes Mellitus Community Based Screening in Minority Populations

NCT01591525
View directory record Official record
Conditions
Type II Diabetes, Diabetes Mellitus
Interventions
Education on risk factors for Type II Diabetes, Education on Type II Diabetes, Education on regular visits to a Primary Care Provider
Behavioral
Lead sponsor
Ethnicity and Disease Community Empowerment Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dorchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00406458
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Normal Saline
Drug · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
14
States / cities
La Jolla, California • Lakewood, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 14, 2026, 4:15 AM EDT
Not yet recruiting Not applicable Interventional

HOPE Intervention for Fitness

NCT07114822
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Harnessing Online Peer Education
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Peer Support Dyads in Churches

NCT03463941
View directory record Official record
Conditions
Peer Support and Chronic Disease, Obesity, Type II Diabetes, Cardiovascular Disease, Cancer
Interventions
Peer Support Dyad Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Not applicable Interventional

Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus

NCT05342545
View directory record Official record
Conditions
Chronic Kidney Diseases, Type2Diabetes
Interventions
Alert-based computerized decision support
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 1 Interventional

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)

NCT00960791
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
AZD1656
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
San Diego, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

NCT02175121
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Placebo, PF-06291874
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Sep 14, 2026, 4:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

NCT07385547
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
GL0034
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 14, 2026, 4:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Low-dose IL-2 in Established T1D - The "PROREG" Study

NCT03243058
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Diabetes, Autoimmune
Interventions
ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm
Biological · Other
Lead sponsor
Jay S. Skyler
Other
Eligibility
8 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

NCT01301092
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
LY2189265
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

NCT01292798
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Sep 14, 2026, 4:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intraoperative OCT Guidance of Intraocular Surgery II

NCT03713268
View directory record Official record
Conditions
Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions
Microscope integrated optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
4 Weeks and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 14, 2026, 4:15 AM EDT
Withdrawn Phase 2 Interventional

A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

NCT05937152
View directory record Official record
Conditions
Diabetic Polyneuropathy
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 3 Interventional

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

NCT00035542
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), metformin HCl, glyburide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
9 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

NCT00760344
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SYR-472, Placebo, Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
105
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 14, 2026, 4:15 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

The Medically Reproducing Bariatric Surgery (MRB) II Study

NCT06363747
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Very Low Calorie Diet
Other
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
25 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 14, 2026, 4:15 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

NCT00260234
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Cultured Islet Cells (human); Encapsulated
Biological
Lead sponsor
Novocell
Industry
Eligibility
20 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 14, 2026, 4:15 AM EDT
Not listed Not applicable Interventional

e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions

NCT02087293
View directory record Official record
Conditions
Diabetes, Depression, Insomnia, Hypertension
Interventions
Intervention arm - automated call and phone-based pharmacist counseling
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
38,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00432276
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin, Pioglitazone, Metformin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 14, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 14, 2026, 4:15 AM EDT